Scientists tested a combination treatment in mice with metastatic melanoma. The therapy involved recombinant human Arylsulfatase B (ARB) alongside the cancer drug pembrolizumab. This research was conducted in a preclinical setting using a specific mouse model, not in humans. The study looked at how the drugs affected tumor growth, survival, and various biological markers inside the animals.
The results showed that the combined treatment inhibited the progression of tumors in both the skin and lungs. Mice receiving this combination lived longer than those without it. The treatment also increased cell death in the tumors and reduced markers associated with tumor spread and invasion.
Because this was a preclinical study in mice, these findings cannot prove the treatment works in people. Safety data for humans is also unknown. Readers should view this as early laboratory evidence that warrants further investigation before any clinical use is considered.